SCHEMBL356405

SCHEMBL356405

[c]1cccc2c1sc1ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.54
MAPT P10636 5/20 0.39
ALDH1A1 P00352 4/20 0.39
RAB9A P51151 3/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LOXL2 Q9Y4K0 1/20 0.34
ALOX15 P16050 1/20 0.34
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
MCL1 Q07820 1/20 0.32
IKBKB O14920 1/20 0.32
LIMK1 P53667 1/20 0.32
KDM4E B2RXH2 1/20 0.32
IDO1 P14902 1/20 0.32
NPC1 O15118 1/20 0.31
TNKS O95271 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20553824 0.98 GPR3 (0.52) GPR3MAPTALDH1A1RAB9AHPGD
SCHEMBL22620062 0.84 KDM4E (0.46) GPR3MAPTALDH1A1RAB9AHPGD
SCHEMBL16668988 0.84 GPR3 (0.33) GPR3
SCHEMBL1335902 0.80 GPR3 (0.32) GPR3
SCHEMBL28512782 0.79 ALDH1A1 (0.33) GPR3MAPTALDH1A1RAB9AHPGD
SCHEMBL28634113 0.77 KDM4E (0.34) GPR3ALDH1A1HPGDSMN1; SMN2IKBKB
Dibenzothiophene SCHEMBL28979299 0.75 GPR3 (0.93) GPR3MAPTALDH1A1RAB9AHPGD
Dibenzothiophene SCHEMBL28979048 0.75 GPR3 (0.93) GPR3MAPTALDH1A1RAB9AHPGD
Dibenzothiophene SCHEMBL28979045 0.75 GPR3 (0.93) GPR3MAPTALDH1A1RAB9AHPGD
Dibenzothiophene SCHEMBL27489159 0.75 GPR3 (0.93) GPR3MAPTALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118284595-A Arylamine compound, organic electroluminescent element, and electronic device 保土谷化学工业株式会社 2024-07-02 CN claimed
WO-2024121084-A1 PREPARATION OF NITRILES MERCK PATENT GMBH (DE) 2024-06-13 WO claimed
CN-117756767-A Preparation method of gamma, gamma-difluoroallylaldehyde compound and derivative thereof 南京林业大学 2024-03-26 CN claimed
EP-3749631-B1 TRIARYLMETHANE COMPOUNDS MITSUBISHI GAS CHEMICAL CO (JP) 2024-03-06 EP claimed
US-11917906-B2 Compounds that can be used in an organic electronic device MERCK PATENT GMBH (DE) 2024-02-27 US claimed
CN-117466947-A Binuclear platinum complexes for OLED applications 香港大学 2024-01-30 CN claimed
US-20230391704-A1 TRIARYLMETHANE COMPOUNDS MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-12-07 US claimed
CN-116854599-A Tetraphenyl ethylene derivative and organic electroluminescent device comprising same 广东省大湾区华南理工大学聚集诱导发光高等研究院 2023-10-10 CN claimed
WO-2023095844-A1 ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE 保土谷化学工業株式会社 2023-06-01 WO claimed
CN-108129431-B Fluorenonaphthofuran derivative and application thereof 北京鼎材科技有限公司 2023-04-07 CN claimed
US-5607926-A ACTIVE AGAINST METHICILLIN RESISTANT BACTERIA MICROCIDE PHARMACEUTICALS, INC. (US) 1997-03-04 US claimed
EP-0754184-A1 CEPHALOSPORIN ANTIBIOTICS Microcide Pharmaceuticals, Inc. (US) 1997-01-22 EP claimed
WO-1995026966-A1 CEPHALOSPORIN ANTIBIOTICS MICROCIDE PHARMACEUTICALS, INC. (US) 1995-10-12 WO claimed
US-5254546-A Hypotensive agent E. I. DU PONT DE NEMOURS AND COMPANY (US) 1993-10-19 US claimed
EP-0524946-A4 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS 1993-03-24 EP claimed
EP-0524946-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1993-02-03 EP claimed
EP-0479892-A1 FUSED-RING ARYL SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-04-15 EP claimed
WO-1991015206-A1 TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-17 WO claimed
WO-1991014367-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-03 WO claimed
WO-1991000281-A2 FUSED-RING ARYL SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-01-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391704-A1 TRIARYLMETHANE COMPOUNDS CBR3, HAX1, HRH3 GPR3 236/4885MAPT 4486/4885ALDH1A1 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.